WAM
ELVN icon

Weiss Asset Management’s Enliven Therapeutics ELVN Stock Holding History

Weiss Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-47,622
Closed -$955K – 663
2025
Q2 		$955K Buy
+47,622
New +$902K 0.01% 337

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Weiss Asset Management's ELVN Position: Q3 2025 in Review

Weiss Asset Management sold out of Enliven Therapeutics (ELVN) in Q3 2025, closing a stake of 47,622 shares — an estimated $955K sold.

Weiss Asset Management first reported a position in ELVN in Q2 2025 and held it in 1 quarter. The position peaked at $955K in Q2 2025. 134 funds tracked by Wall St. Rank hold ELVN as of Q3 2025.

  • Weiss Asset Management reported no remaining Enliven Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Weiss Asset Management sold 47,622 Enliven Therapeutics shares in Q3 2025, an estimated $955K.
  • Weiss Asset Management first reported a position in Enliven Therapeutics in Q2 2025 and held it in 1 quarter.
  • Weiss Asset Management's Enliven Therapeutics position peaked at $955K in Q2 2025.
  • 134 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2025.

Based on Weiss Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.